METABOLIC THERAPY IN WOMEN WITH PLACENTARY DYSFUNCTION

Abstract

The need for micronutrients during pregnancy increases by 25% due to increased consumption of the fetal organism. Omega-3 PUFAs are not synthesized in the human body and are indispensable, and are also part of the structural components of not only the brain lipids, but also the cells of the immune, cardiovascular systems and the visual analyzer. The use of Omega-3 PUFA promotes blood circulation in the mother-placenta-fetus system, improves the rheological properties of blood, prevents the development of preeclampsia and affects the reduction of perinatal complications. High efficiency, good tolerability, absence of teratogenic and embryotoxic actions allow wide use of Omega-3 PUFA in obstetric-gynecological practice.The aim of the study was a comparative analysis of the course of pregnancy, childbirth and the state of newborns in pregnant women with placental dysfunction who received metabolic therapy and those who did not receive it.Material and methods of the study. A prospective analysis of the course of pregnancy, childbirth and the state of newborns was conducted in 130 pregnant women with placental dysfunction (PD) at the gestation period of 28-34 weeks, which gave birth in Odessa Regional Perinatal Center of the Regional Clinical Hospital. Patients were divided into 2 groups: I – the main group (MG) (n = 67) – pregnant women with PD who received metabolic therapy in the form of 300 mg of Omega-3 PUFA per day for 4 weeks, II – control group (CG) ( n = 63) – pregnant women with PD who did not receive metabolic therapy. In the examined patients of MG, it was found that, according to the Doppler study of FPC, pregnancy was complicated by violations of the fetus-placental blood flow of the II st. in 36 (53,7%) and III st. – 8 (12,0%). And in pregnant women of CG is significantly more likely – 45 (71,4%) and 14 (22,2%), respectively. Such complications of newborns as RDS – 31 (49,2%), IVH – 33 (52,4%), HIE – 49 (77,8%), NEC – 34 (54,0%) were more often expressed in women of CG.Conclusions. The use of Omega-3 PUFA improves perinatal outcomes, reduces the incidence of IVH 17 (25,4%), reduces the frequency of HIE 27 (40,3%), reduces the incidence of NEC 16 (23,9%), and reduces the the risk of developing RDS in premature infants 22 ( 32,8%). Newborns of MG pregnant had higher scores on the Apgar scale (1st. min. – 6,66 ± 1,0, and 5 th. -7,26 ± 0,81 point) compared to the newborns of women of the CG (1st. min. – 5,65 ± 1,54 p., the 5 th. – 6,38 ± 1,68 p.). The average weight of children at birth was greater in the MG (1608 ± 292 g, in the CG-1470 ± 304 g.).